Group 1 - Kenvue's stock has faced challenges in 2025, particularly after controversial comments regarding Tylenol's safety during pregnancy [1] - Despite negative press, Kenvue reported a Q3 2025 adjusted profit of $0.28 on sales of $3.8 billion [2] - Kimberly-Clark announced a $48.7 billion acquisition of Kenvue, aiming to combine their consumer offerings, which include 10 billion-dollar brands [4] Group 2 - Following the merger announcement, Kenvue's stock rose by 17.5%, while Kimberly-Clark's stock fell by 12% [4] - The combined companies are projected to have $32 billion in annual sales and $3.4 billion in annual profit, with potential cost savings of $2.1 billion [6] - If the merger is successful, the combined entity could achieve a P/E ratio below 8 times earnings, indicating a potentially attractive investment [8]
Why Tylenol Maker Kenvue Stock Just Popped